Nutriband Inc. (NASDAQ:NTRB) Sees Large Decline in Short Interest

Nutriband Inc. (NASDAQ:NTRB) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 54,900 shares, a drop of 24.4% from the December 31st total of 72,600 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily volume of 153,100 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Noble Financial assumed coverage on shares of Nutriband in a research note on Wednesday, January 22nd. They set an “outperform” rating and a $13.00 price target on the stock.

Nutriband Price Performance

Shares of NTRB traded up $0.39 during trading hours on Friday, reaching $8.29. The company had a trading volume of 110,336 shares, compared to its average volume of 449,503. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $4.96 and a 200-day simple moving average of $5.51. Nutriband has a 12-month low of $2.22 and a 12-month high of $11.78. The company has a market capitalization of $92.10 million, a price-to-earnings ratio of -11.68 and a beta of 0.99.

Nutriband (NASDAQ:NTRB) last released its quarterly earnings results on Tuesday, December 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%. Research analysts expect that Nutriband will post -0.6 earnings per share for the current year.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.